Sun Pharmaceutical Industries Ltd Share Price

Overview

Sun Pharmaceutical Industries Ltd share price is currently ₹1,872.52, down by - ₹4.84 (0.26%) from its previous closing price of ₹1,877.36. The share price has declined -2.55% over the past month and gained 16.39% over the past year. The stock's 52-week low and high are ₹1,521.76 and ₹2,009.08, respectively. Sun Pharmaceutical Industries Ltd has a market capitalisation of ₹ 4,60,000.00 Cr. The share price was last updated on 20 Aug 2026, 03:59 PM IST.

Sun Pharmaceutical Industries Ltd

SUNPHARMA

₹0.00

- ₹4.84

0.26%

Healthcare

₹0.00(%)1D

Updated: 20 Aug 2026, 03:59:10 pm IST

Market Data

Open Price

₹1,868.51

Prev. Close

₹1,877.36

₹1,858.61

Day Low

₹1,880.35

Day High

₹1,521.76

52 Week Low

₹2,009.08

52 Week High

HealthcarePharmaceuticals & Drugs

CategoryLarge Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

37.15

Sector PE

42.16

PB Ratio

5.38

Sector PB

5.82

EPS

50.41

Dividend Yield

0.91

Today's Volume

889.497 K

5 Day Avg. Volume

1.406 M

PEG Ratio

7.37

Market Cap.

₹ 4,60,000.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Actions	Ex-Date	Record-Date
DividendsFinal Dividend of 500% at ₹5/Share	07-Jul-2026	07-Jul-2026
DividendsInterim Dividend of 1100% at ₹11/Share	05-Feb-2026	05-Feb-2026
DividendsFinal Dividend of 550% at ₹5.5/Share	07-Jul-2025	07-Jul-2025
DividendsInterim Dividend of 1050% at ₹10.5/Share	06-Feb-2025	06-Feb-2025

Mutual Fund Ownership

Mutual Fund Holder	Jun 26 Shares held	Jul 26 Shares held
SBI Nifty 50 ETF	2.03 Cr	2.04 Cr (0.72%)
SBI BSE Sensex ETF	1.42 Cr	1.43 Cr (0.88%)
ICICI Prudential Value Fund - Growth	1.55 Cr	1.38 Cr (11.01%)
ICICI Prudential Equity & Debt Fund - Growth	99.57 Lac	98.53 Lac (1.05%)
ICICI Prudential Large Cap Fund - Growth	1.07 Cr	90.69 Lac (15.44%)

Show all holdings

About Sun Pharmaceutical Industries Ltd 👋

Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company with a presence in specialty therapies, generics and consumer healthcare products. The Company's global specialty portfolio spans products in dermatology, ophthalmology, and onco-dermatologym, among others. The Company manufactures and markets a large basket of pharmaceutical formulations across chronic and acute therapies, including generic, branded generics, specialty and complex products, over-the-counter (OTC), antiretrovirals (ARV), Active Pharmaceutical Ingredients (API), and intermediates. Its portfolio spans multiple dosage forms, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, and others. Its portfolio also includes UNLOXCYTTM, an anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma.